RxDoctor Payments Data

Paul Saladino, MD

Internal Medicine · Newburgh, NYNPI 1306951736

Payments from drug & device makers

$2,320in general payments, 2019–2025

Across 90 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$544
  • Gilead$334
  • AstraZeneca$210
  • Axsome Therapeutics, Inc.$199
  • Indivior Inc.$176
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$126
  • plus $731 from 14 others

What the payments were for

  • Food & beverage$2,30899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,320 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$105,968
Medicare patients
143
Services billed
1,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$62,451
OzempicSemaglutide42$37,876
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl167$30,381
EliquisApixaban24$29,408
MounjaroTirzepatide21$22,232
JanuviaSitagliptin Phosphate24$20,183
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,214
RybelsusSemaglutide13$17,999
GlyxambiEmpagliflozin/Linagliptin11$9,590
SymbicortBudesonide/Formoterol Fumarate28$6,993
SuboxoneBuprenorphine Hcl/Naloxone Hcl18$6,639
Albuterol Sulfate HfaAlbuterol Sulfate142$4,277
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,581
Pregabalin40$2,797
Atorvastatin Calcium261$2,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$544$55,87555 claims
Lilly USA, LLCMounjaro$73$22,23221 claims
MerckJanuvia$120$20,18324 claims
GSKTrelegy Ellipta$23$18,21424 claims
AstraZenecaSymbicort$210$6,99328 claims
Indivior Inc.Suboxone$176$6,63918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Newburgh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →